<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654979</url>
  </required_header>
  <id_info>
    <org_study_id>SFF-104</org_study_id>
    <nct_id>NCT00654979</nct_id>
  </id_info>
  <brief_title>A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter</brief_title>
  <official_title>A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RMT Medical Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RMT Medical Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and effectiveness of the SafeFlo filter for permanent protection&#xD;
      against pulmonary emboli. All patients will be selected to receive the filter according to&#xD;
      the stated inclusion / exclusion criteria after consultation between the attending physician&#xD;
      and interventional radiologist. Patients with a permanent implantation will be followed for&#xD;
      up to 6 months. Clinical success will be defined as no occurrences of any of the following&#xD;
      events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of&#xD;
      permanent filter patients considered to be a clinical success will be the primary efficacy&#xD;
      parameter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization.</measure>
    <time_frame>6 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval.</measure>
    <time_frame>3 and 6 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SafeFlo IVC Filter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SafeFlo IVC Filter</intervention_name>
    <description>SafeFlo IVC Filter</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Traditional indications for vena cava filter in patients with established DVT or PE,&#xD;
             including (40):&#xD;
&#xD;
               -  Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one&#xD;
                  or more of the following:&#xD;
&#xD;
                    1. Contraindication to anticoagulation&#xD;
&#xD;
                    2. Complication of anticoagulation&#xD;
&#xD;
                    3. Failure of anticoagulation&#xD;
&#xD;
                         -  Recurrent PE despite adequate anticoagulation therapy&#xD;
&#xD;
                         -  Inability to achieve adequate anticoagulation&#xD;
&#xD;
                    4. Poor compliance with anticoagulation medications&#xD;
&#xD;
          -  Extended indications for vena cava filter placement in patients with established DVT&#xD;
             or PE, including the following (31, 40):&#xD;
&#xD;
               -  Large free-floating thrombus in the iliac vein or IVC;&#xD;
&#xD;
               -  Following massive PE in which recurrent emboli may prove fatal;&#xD;
&#xD;
               -  During/after surgical or transcatheter embolectomy;&#xD;
&#xD;
               -  Filter placement in high-risk trauma and orthopedic patients:&#xD;
&#xD;
          -  High risk trauma or orthopedic patients who cannot receive anticoagulation because of&#xD;
             increased bleeding risk, and have one or more of the following injury patterns (31,&#xD;
             40):&#xD;
&#xD;
               1. Severe closed head injury (GCS &lt; 8);&#xD;
&#xD;
               2. Incomplete spinal cord injury with para or quadriplegia;&#xD;
&#xD;
               3. Complex pelvic fractures with associated long-bone fractures;&#xD;
&#xD;
               4. Multiple long bone fractures.&#xD;
&#xD;
          -  Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All patients under 18 years of age.&#xD;
&#xD;
          -  All patients undergoing emergency procedures.&#xD;
&#xD;
          -  All patients with abnormal IVC anatomy or pathology of the IVC such as thrombosis or&#xD;
             tumor which prevent safe filter implantation.&#xD;
&#xD;
          -  All patients with an IVC diameter which precludes oversizing of the filter platform.&#xD;
&#xD;
          -  All patients with active infection / bacteremia.&#xD;
&#xD;
          -  All patients with sensitivity to contrast media.&#xD;
&#xD;
          -  Uncorrectable severe coagulopathy (e.g., patients with liver or multisystem failure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Cynamon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Name Hospital</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251 Air Force Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitas Hospital</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Margaret Hospital</name>
      <address>
        <city>Dumfermline</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rafaelmedical.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

